Date: 2013-07-29
Type of information: Termination of an agreement
Compound: new formulation of a fast-acting insulin analog
Company: Adocia (France) Eli Lilly (USA)
Therapeutic area: Metabolic diseases
Type agreement: development
commercialisation
Action mechanism: This new formulation is based on Adocia proprietary technology, BioChaperone®.
Disease:
Details: * On December 2011, Adocia has announced that the company has confirmed the value of its technology BioChaperone® by signing at the end of 2011 a license and collaborative agreement with a major pharmaceutical group for the development and commercialization of a new formulation of fast-acting insulin analog.
Financial terms: Under the terms of the agreement, Adocia has received an up-front payment in the amount of $ 10 million (€ 7.6 million). Additional milestone payments up to $ 156 million are also set depending on the achievement of predefined milestones. Moreover, Adocia is entitled to receive incremental royalties on net sales of the product.
Latest news:
* On July 29, 2013, Adocia has announced that it had agreed with Eli Lilly not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone® technology for the formulation of fast acting insulin analog formulated with the BioChaperone® technology. Consequently, the two companies have terminated the collaboration. Adocia plans to test a BioChaperone® insulin analog formulation on type I diabetic patients. For this, the company intends "to conduct, before year end in Germany, a clinical trial on one or more formulations of insulin analog. This trial will be carried out in parallel to the one already scheduled with HinsBet®, our formulation of human insulin” said Olivier Soula, Deputy General Manager and Director R&D.
